An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020
Authors:
Open Access
- 1 May 2022
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 27 (5) , 1236-1250
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Achievements and challenges of the Sakigake designation system in JapanBritish Journal of Clinical Pharmacology, 2021
- U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review ProgramClinical Cancer Research, 2021
- Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content AnalysisValue in Health, 2020
- Simultaneous development of zanubrutinib in the USA and ChinaNature Reviews Clinical Oncology, 2020
- Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated ApprovalJAMA Internal Medicine, 2019
- Expediting Drug Development: FDA’s New Regenerative Medicine Advanced Therapy DesignationTherapeutic Innovation & Regulatory Science, 2019
- FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug ApprovalsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and BiologicsJAMA Oncology, 2018
- Clinical development success rates for investigational drugsNature Biotechnology, 2014
- Orphan drugs: the regulatory environmentDrug Discovery Today, 2013